Scholarlink

Background <p>Breast cancer (BC), the most aggressive cancer in women, continues to exhibit serious health concerns globally. However, the existing limitations in current therapeutics demand novel, broad-spectrum and cost-effective treatment. Herbal medicines are currently used as effective anticancer treatments, comprising specific plant-derived bioactive compounds. Jervine, a steroidal alkaloid, has proven to have anticancer activities; hence, its therapeutic mechanism in contributing to BC tumorigenesis remains incompletely elucidated.</p> Objective <p>This study investigates the molecular mechanism of action of jervine’s anticancer efficacy against BC via in silico and in vitro analyses.</p> Methods <p>In silico analysis, including network pharmacology, pharmacokinetics, molecular docking, and molecular dynamics simulations, was performed to explore jervine’s therapeutic potential against BC targets. Further,an <i>invitro</i> analysis was evaluated for its cytotoxic effects using MDA-MB-231 triple-negative breast cancer (TNBC) cells, using the MTT assay, followed by gene expression analysis via RT-PCR.</p> Results <p>The combined findings from network pharmacology, molecular docking, and molecular simulation analyses clearly demonstrated that jervine possesses favourable drug-like properties and forms stable interactions with multiple Wnt signalling targets (WNT5A, FZD5, LRP6), as well as key modulators from other pathways, including BMP4 (a member of the TGF-β family) and SHH (a central component of Hedgehog signalling), all of which are associated with breast cancer. In vitro analysis of MDA-MB-231 cells using the MTT assay showed that jervine exhibited significant cytotoxic effects, with IC<sub>50</sub> values of 18.55&#xa0;μM at 24&#xa0;h and 13.23&#xa0;μM at 48&#xa0;h. Further, gene expression analysis particularly emphasized that jervine significantly controlled the dysregulated WNT signalling targeted genes (Wnt 5a, DVL2, FZD5, LRP6) and including SHH, BMP4 genes mRNA expression levels and thereby inhibited the proliferation of BC cells. Further, these in vitro results coincide with the findings of the computational studies.</p> Graphical abstract <p></p> <p>The graphical abstract represents a research workflow that explores the anticancer effects of the compound jervine on breast cancer through various in silico and in vitro processes, including computational analysis, biological evaluation, and mechanistic insights. The illustration highlights the molecular interactions from in silico and in vitro studies of jervine's therapeutic potential in breast cancer (BC).</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Jervine-induced suppression of triple-negative breast cancer (TNBC) cells growth through the regulation of Wnt signaling pathway- an in-silico and in-vitro approach

  • 期刊论文

  • 发表日期：

    2026年2月5日

查看全文
  • Anupriya Eswaran,
  • Sathan Raj Natarajan,
  • Selvaraj Jayaraman,
  • Javed Masood Khan,
  • Sharmila Jasmine,
  • Vishnu Priya Veeraraghavan

摘要

Background

Breast cancer (BC), the most aggressive cancer in women, continues to exhibit serious health concerns globally. However, the existing limitations in current therapeutics demand novel, broad-spectrum and cost-effective treatment. Herbal medicines are currently used as effective anticancer treatments, comprising specific plant-derived bioactive compounds. Jervine, a steroidal alkaloid, has proven to have anticancer activities; hence, its therapeutic mechanism in contributing to BC tumorigenesis remains incompletely elucidated.

Objective

This study investigates the molecular mechanism of action of jervine’s anticancer efficacy against BC via in silico and in vitro analyses.

Methods

In silico analysis, including network pharmacology, pharmacokinetics, molecular docking, and molecular dynamics simulations, was performed to explore jervine’s therapeutic potential against BC targets. Further,an invitro analysis was evaluated for its cytotoxic effects using MDA-MB-231 triple-negative breast cancer (TNBC) cells, using the MTT assay, followed by gene expression analysis via RT-PCR.

Results

The combined findings from network pharmacology, molecular docking, and molecular simulation analyses clearly demonstrated that jervine possesses favourable drug-like properties and forms stable interactions with multiple Wnt signalling targets (WNT5A, FZD5, LRP6), as well as key modulators from other pathways, including BMP4 (a member of the TGF-β family) and SHH (a central component of Hedgehog signalling), all of which are associated with breast cancer. In vitro analysis of MDA-MB-231 cells using the MTT assay showed that jervine exhibited significant cytotoxic effects, with IC50 values of 18.55 μM at 24 h and 13.23 μM at 48 h. Further, gene expression analysis particularly emphasized that jervine significantly controlled the dysregulated WNT signalling targeted genes (Wnt 5a, DVL2, FZD5, LRP6) and including SHH, BMP4 genes mRNA expression levels and thereby inhibited the proliferation of BC cells. Further, these in vitro results coincide with the findings of the computational studies.

Graphical abstract

The graphical abstract represents a research workflow that explores the anticancer effects of the compound jervine on breast cancer through various in silico and in vitro processes, including computational analysis, biological evaluation, and mechanistic insights. The illustration highlights the molecular interactions from in silico and in vitro studies of jervine's therapeutic potential in breast cancer (BC).